The representative miRNAs miR-21, miR-221/222, and miR-181b, which are associated with liver diseases, have been found to promote liver fibrosis via the TGF-β and NF-κB pathways [107], and miR-221 has been shown to be involved in the cyclin-dependent kinase inhibitor (CDKN) 1C and CDKN1B, cytokine signaling, E-cadherin, PTEN (phosphatase and tensin homologs) [108], and Bcl-2 modifying factor, which regulate various targets involved in NASH progression. The gene discussed is TGFB1; the disease is metabolic dysfunction-associated steatohepatitis.